Dylan Beynon - Mindbloom: The Next Chapter in Mental Health and Wellbeing

Dylan Beynon - Mindbloom: The Next Chapter in Mental Health and Wellbeing

In this episode, Kyle sits down with Dylan Beynon, founder of Mindbloom, NYC based mental health and wellbeing platform. In the show they talk about how Mindbloom differs from other centers, paving the way for accessibility and affordability.

3 Key Points:
  1. Mindbloom is a next-generation mental health platform, catered to accessibility and affordability.
  2. They use ketamine tablets, different from lozenges and any other method. The tablets are held in the mouth and then spit out to avoid entering the liver, causing a sedation-like experience.
  3. Mindbloom differentiates themselves from other psychedelic therapy options by using a patient-choice model, to keep it affordable for those who need it. They offer the 4-week therapy model and give patients the option to choose 'add-ons' like extra integration.

Support the show Navigating Psychedelics

Show Notes About Dylan
  • Dylan is not a clinician or a doctor, he is an entrepreneur and a psychedelic medicine and therapeutic ketamine patient
    • These medicines have been transformative in his life and he wants to bring their benefits to the public
  • He grew up in a family that suffered greatly from mental illness
    • He lost his mother to addiction
  • He discovered positive psychology
    • When learning about the science of happiness, he realized that he wasn't happy
    • He was in business school and wanted to be a banker and make a ton of money
    • He soon realized that money doesn't buy happiness, and he thought maybe everything he was doing was a lie
  • He was self medicating with psychedelics
  • About 5 years ago he heard about psychedelic therapy
  • About 18 months ago he started working with a clinician doing ketamine therapy
  • He saw that when it's done in a therapeutic context, it can have a profound effect for people to get the most out of it
  • "Recreational vs therapeutic use is a false dichotomy" - Dylan
Mindbloom
  • The goal is to build the next-generation mental health platform
  • Right now they are doing Ketamine therapy
  • They are trying to make it accessible by making it affordable
  • They are trying to bring an elevated client experience, which they do with the space and software
Software Background
  • Voters Friend - a platform to help inform voters on the candidates, to increase access to democracy
  • Mighty - increasing access to social justice
  • Mindbloom - increase access to psychedelic medicines
Differentiation
  • The protocols that Mindbloom are using are capped
  • They are increasing access to the medicines, making it affordable
    • They keep it at $150-$250 a session, where at most Ketamine Therapy centers, it can range from $1000-$2000 a session
  • Dylan says he makes this possible by bringing in technology and software tools to make the sessions for efficient and effective
    • They use patient choice care, where the patient can use their best judgement on how in depth they want their treatment
  • They can 'add on' extra integration time onto the therapy session, or choose not to
    • This keeps the price down and accessible for each individual patient if need be
  • Mindbloom is a 4 session program, usually 1-2 months
  • They use the platform to have the client practice using the information in the weeks between each session, so they can practice integration even when not with a therapist or in session
The Program
  • The clinician prescribes a 4 week Ketamine Therapy session for anxiety and depression
    • The clinician will schedule a video interview to learn their symptoms
    • Then they will meet in person and build an integration program if needed
    • Its $1000 for the 4 session program and $600 for the renewal program
  • They use Ketamine tablets (similar to lozenges but faster acting)
    • They're not swallowing it, they spit it out after
    • If they swallow it, it breaks down in the liver into nor-ketaine, and that produces a sedative effect
  • After they spit it out, there is about an hour of music with no vocals
  • After the session, they move to an integration room where they are journaling
  • The protocols at Mindbloom were based on the MAPS protocol
  • They don't have a clinician in the room during the experience, only for after the experience
  • Dylan is looking to expand to other locations
    • A lot of people request couples or group therapies, so they will be taking that into consideration when building new locations
Final Thoughts
  • The more people who are thinking critically about this and putting their intentions into making this more accessible the better
  • There needs to be more gentle conversation around psychedelics and therapy, especially around the people that are still so unaware about this field
    • We should bring sacredness, specialness, and care to the conversation with those who might still be afraid about it
Links

Website

About Dylan Beynon

Dylan is the Founder & CEO of Mindbloom, an NYC-based mental health and wellbeing startup helping people expand their human potential with clinician-prescribed, guided psychedelic medicine experiences. There, he is partnering with clinicians, technologists, researchers, and patients to increase access to science-backed treatments, starting by reducing the cost of ketamine therapy for depression and anxiety by over 65%. Dylan is a 10-year psychedelic medicine patient and 3-time tech entrepreneur with both $100M+ in funding and an exit in his prior startups, which were focused on increasing access to justice and democracy. Dylan graduated from The Wharton School at The University of Pennsylvania.

Get a 30 day free audible trial at audibletrial.com/psychedelicstoday

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(778)

PT 660 - Josh Lipson & Roman Palitsky: Psychedelic Harms and the Post-Psychedelic Challenges Study

PT 660 - Josh Lipson & Roman Palitsky: Psychedelic Harms and the Post-Psychedelic Challenges Study

This is an important discussion about harms, and what we should be doing about them. Josh and Roman are working on a major study at Emory University to answer some of the basic and outstanding questio...

12 Aug 1h 12min

PT 659 - Megan Bowers & Mikayla Hellwich

PT 659 - Megan Bowers & Mikayla Hellwich

This is a special episode featuring two of our favorite organizations. DanceSafe and Shulgin Foundation. Listen to Joe Moore record with the heads of these orgs and learn about how you may be able to ...

5 Aug 1h 20min

PT 658 - Mareesa Stertz – Sphinx Gate Beyond Burning Man: Psychedelic Healing Without Psychedelics

PT 658 - Mareesa Stertz – Sphinx Gate Beyond Burning Man: Psychedelic Healing Without Psychedelics

My friend Mareesa joins us again on PT to discuss art, integration, psychedelic experiences without drugs, the heros journey and her smaller sphinxes that may start touring the country! Enjoy! Here ar...

31 Jul 1h 15min

PT 657 - Rachel Turetzky PhD & Douglas S. Wingate DTCM: The Eight-Circuit Model, Metaprogramming, and Psychedelic Therapy

PT 657 - Rachel Turetzky PhD & Douglas S. Wingate DTCM: The Eight-Circuit Model, Metaprogramming, and Psychedelic Therapy

Kyle and Joe interview Rachel Turetzky & Douglas S. Wingate about their perspectives on the Wilson\Leary 8 Circuit Model of consciousness. They recently released a CE approved program on Psychedelic E...

23 Jul 1h 18min

PT 656 - Travis Tyler Fluck: Denver Mushroom Decriminalization, Mutual Aid, and the Future of Psychedelic Culture

PT 656 - Travis Tyler Fluck: Denver Mushroom Decriminalization, Mutual Aid, and the Future of Psychedelic Culture

Denver mushroom decriminalization changed the national conversation around psilocybin access, personal use, and grassroots psychedelic reform. In this episode of Psychedelics Today, Joe Moore speaks w...

11 Mai 1h 43min

PT 655 - Martha Hammel and Tasia Poinsatte - Aspen Psychedelic Symposium

PT 655 - Martha Hammel and Tasia Poinsatte - Aspen Psychedelic Symposium

Aspen Psychedelic Symposium is the focus of this conversation with Martha Hammel of the Aspen Psychedelic Resource Center and Tasia Poinsatte of Healing Advocacy Fund. They join Joe Moore to discuss t...

8 Mai 54min

PT 654 - Erica Rex - Seeing What Is There

PT 654 - Erica Rex - Seeing What Is There

Seeing What Is There is at the center of this conversation with journalist and author Erica Rex, who joins Joe Moore to discuss her book Seeing What Is There: My Search for Sanity in the Psychedelic E...

23 Apr 1h 20min

PT 653 - Dr. Michael Alpert and Peter Alberding - ALS, Existential Distress, and Ketamine Therapy

PT 653 - Dr. Michael Alpert and Peter Alberding - ALS, Existential Distress, and Ketamine Therapy

ALS and ketamine therapy are at the center of this conversation with psychiatrist Dr. Michael Alpert and Peter Alberding, who was diagnosed with ALS in late 2023. Alpert is a Boston-area psychiatrist ...

16 Apr 1h 19min

Populært innen Vitenskap

fastlegen
tingenes-tilstand
rss-nysgjerrige-norge
romkapsel
liberal-halvtime
rekommandert
jss
villmarksliv
dekodet-2
tomprat-med-gunnar-tjomlid
rss-paradigmepodden
vett-og-vitenskap-med-gaute-einevoll
fjellsportpodden
abels-tarn
sinnsyn
rss-rekommandert
rss-overskuddsliv
diagnose
nordnorsk-historie
rss-inn-til-kjernen-med-sunniva-rose